The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth.
Huchet
M
M
Institut Henri Beaufour, 5 avenue du Canada, 91966 Les Ulis, France.
Demarquay
D
D
Coulomb
H
H
Kasprzyk
P
P
Carlson
M
M
Lauer
J
J
Lavergne
O
O
Bigg
D
D
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006131:Growth Inhibitors / Q000494:pharmacology*; D006801:Humans; D000077146:Irinotecan; D008297:Male; D051379:Mice; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000473:pathology; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; C121907:BN 80927; D004791:Enzyme Inhibitors; D006131:Growth Inhibitors; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D000077146:Irinotecan; D002166:Camptothecin